I've spent nearly all my working life as a journalist. I covered the rise and fall of the dot-com era in the second half of the 1990s, then switched to life sciences in the new millennium. I've written about the strategy, financing and scientific breakthroughs of biotech for The Deal, Elsevier's Start-Up, In Vivo and The Pink Sheet, and now Xconomy.
[Editor’s note: Ben Fidler contributed to this report] The week of frenetic data sharing, deal talking, and party hopping of the J.P. Morgan Healthcare Conference—and the events that have... Read more »
Oh, the power of a Donald Trump sound bite. On the campaign trail and as president-elect he has made occasional noises about drug pricing—giving the U.S. Medicare system, the largest buyer... Read more »
The first test of pharmaceutical giant Allergan’s promise to behave responsibly came last week. The firm acknowledged price hikes on several drugs that stayed—sometimes barely—under the 10 percent limit that CEO... Read more »
Happy new year, everyone. Are you all strapped in? Tray tables in the locked and upright position? As Bette Davis once said, “It’s going to be a bumpy night.”
The... Read more »
Information technology has wound itself so deeply into healthcare, this might be the year that the term “digital health”—used roughly to distinguish health-related hardware and software from drugs and medical devices—becomes... Read more »
You’ve probably seen the Internet memes. “When 2016 started, I looked like this. [Insert picture of young Leo DiCaprio.] Now I look like this. [Leo, with mountain beard, after mud-wrestling... Read more »
[Updated 12/19/16, 5:33 p.m. ET. See below.] The two sides fighting over ownership of the landmark gene editing technology CRISPR-Cas9 are waiting for a decision from a panel of... Read more »
The 21st Century Cures Act is now law. New York wants to play in the biotech big leagues. The FDA under Trump will have license to approve drugs faster and could... Read more »
A new stem cell therapeutics company, BlueRock Therapeutics, has launched with $225 million in funding from international healthcare giant Bayer and Versant Ventures. Using work from Nobel Prize winner Shinya Yamanaka... Read more »
What a week. The 21st Century Cures Act is now waiting President Obama’s promised signature after easy passage through Congress. President-elect Donald Trump re-stirred the drug-pricing pot with comments in Time... Read more »
Speaking at a conference in San Francisco Wednesday, geneticist Craig Venter revealed that he had just had surgery for prostate cancer three weeks ago. A health workup at his own high-end... Read more »
Juno Therapeutics is still mulling next steps for its lead product, an experimental cancer immunotherapy now stuck in limbo because five of 68 adult leukemia patients in its current study, a... Read more »
The U.S. Senate cleared the way for the 21st Century Cures Act, an omnibus healthcare spending and reform bill, by voting 85-13 to end debate this evening.
It passed the House... Read more »
[Updated, 12/5/16, 4 p.m. See below.] If you’re following cancer immunotherapy, you might feel a bit swamped by this week’s wave of clinical data from experimental programs that turn... Read more »
By a 392 to 26 vote, the U.S. House of Representatives has passed the omnibus healthcare legislation called the 21st Century Cures Act, bringing new funding for top Obama administration health... Read more »
Two big pieces of the Trump healthcare puzzle have fallen into place. The President-elect’s transition team has nominated Georgia Republican congressman Tom Price to be Health and Human Services secretary. It... Read more »
Juno Therapeutics (NASDAQ: JUNO), a developer of experimental “CAR-T” cancer therapies derived from a patient’s own immune cells, reported this morning that two more patients have died during a trial... Read more »
[Updated, 11/22/16, 5:42 p.m. See below.] Among the many questions swirling around the incoming Trump administration is the fate of ambitious biomedical science projects that require federal funding. What... Read more »
Speculation swirled this week around the incoming U.S. president’s intent to make good on his angry campaign rhetoric on drug prices, while the Associated Press reported that naming-and-shaming—that is, Congress hauling... Read more »
December 15, 2016
© 2007-2017, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.